がん診断薬の世界市場：規模、シェア・動向分析レポート - 製品別、タイプ別、用途別、最終用途別、検査タイプ別、セグメント予測、2024～2030年

がん診断薬市場の成長と動向：

世界のがん診断薬の市場規模は、2030年までに1,623億1,000万米ドルに達する見込みです。

同市場は2024～2030年にかけてCAGR 6.16％で拡大すると予測されています。複数の組織によるがんに関する意識向上プログラムの増加が、世界の診断製品の需要増加の主な要因です。全国子宮頸がん連合、WHO、CDC、米国予防サービス作業部会、その他が子宮頸がん検診を増やすために行っている提携や協力は、予測期間中の市場成長を押し上げると予想される主な要因の一つです。

そのため、いくつかの国では、早期診断のための検診を増やし、既存の患者を支援するための対策を実施しています。例えば、Ayushman BharatとPrime Minister's National Relief Fundは、治療中に援助を必要とする患者のためにインド政府によって開始されました。同様に、インド政府のバイオテクノロジー省は、診断と治療への安価なアプローチのための調査を実施するために、英国がん研究省と契約を締結しました。

リキッドバイオプシーソリューションは、臨床応用が容易であることから、MCED検査として採用されるケースが増えています。近年では、包括的かつ複数のがん診断薬アプローチで規制当局の承認を得ています。この分野における画期的な進歩や早期発見のための進行中の研究が市場の成長に寄与しています。さらに、循環腫瘍DNA、細胞外小胞、循環腫瘍細胞などの技術は、より良いがん治療への道を開いています。汎用性の高い技術は、リキッドバイオプシーの可能性を最大限に引き出すための統合的なソリューションを提供することができます。

コンパニオン診断薬を使用する利点は、製薬企業や診断企業が負担する時間とコストを全体的に削減できることです。新規分子の開発と商業化に要する時間は一般的に10年から15年です。診断薬と医薬品の共同開発により、規制当局の承認プロセスが促進され、コストが大幅に削減されます。2016年に治療薬とIVDコンパニオン診断薬の開発に関するFDAガイダンスドラフトが公表されて以来、多くのメーカーががん領域でのコンパニオン診断薬の開発を奨励しています。これは予測期間中の市場成長にプラスの影響を与えると予測されます。

がん診断薬市場のレポートハイライト

• 製品別では、消耗品セグメントが2023年に59.98%の最大シェアを占め、予測期間中に最も速い成長率が見込まれます。
• タイプ別では、体外診断薬（IVD）セグメントが2023年に52.75%のシェアで支配的でした。
• 乳がん用途分野は、国民全体に認識を広めるためのイニシアチブの増加や研究開発活動の増加により、予測期間中に大きく成長する見込みです。
• 最終用途別では、効率的な外来患者サービスを提供する検査部門が市場を独占しています。病院分野は、入院患者の増加に起因して、今後数年間で著しい成長が予測されます。
• 生検分野は、疾患の早期発見を含む検査に伴う様々な利点により、大きな成長率で成長すると予測されています。
• 北米は、新しい診断検査の承認件数の増加により、2023年の世界がん診断薬市場を席巻しました。
• アジア太平洋は、有病率の上昇と主要企業の存在により、今後大幅な成長が見込まれます。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 市場変数、動向、範囲

• 市場セグメンテーションと範囲
• 市場系統の見通し
  • 親市場の見通し
  • 関連/付随市場の見通し
• 市場力学
• 市場促進要因
  • がん罹患率の上昇
  • 技術の進歩
  • 官民組織による取り組みの高まり
  • 新しい検査ソリューションの開発のための広範な研究開発
• 市場抑制要因分析
  • 画像診断のコストが高い
  • 放射線被曝によりCTスキャンの使用が制限される可能性が高い
  • 再生画像診断システムの採用の増加
• 事業環境分析
  • SWOT分析：要因別（政治・法律、経済・技術）
  • ポーターのファイブフォース分析
  • COVID-19感染症の影響分析

第4章 製品ビジネス分析

• がん診断薬市場：製品変動分析
• 機器
  • 機器市場、2018～2030年
  • 病理ベース機器
  • 画像機器
  • その他
• 消耗品
  • 消耗品市場、2018～2030年
• サービス
  • サービス市場、2018～2030年

第5章 タイプビジネス分析

• がん診断薬市場：タイプの変動分析
• IVD
  • IVD市場、2018～2030年
  • IVD市場、タイプ別、2018～2030年
  • IVD市場、技術別、2018～2030年
• LDT
  • LDT市場、2018～2030年
• イメージング
  • 映像市場、2018～2030年
  • 磁気共鳴画像法（MRI）
  • コンピュータ断層撮影（CT）
  • 陽電子放出断層撮影法（PET）
  • マンモグラフィー
  • 超音波
  • その他

第6章 用途ビジネス分析

• がん診断薬市場：用途変動分析
• 乳がん
  • 乳がん市場、2018～2030年
• 結腸直腸がん
  • 結腸直腸がん市場、2018～2030年
• 子宮頸がん
  • 子宮頸がん市場、2018～2030年
• 肺がん
  • 肺がん市場、2018～2030年
• 前立腺がん
  • 前立腺がん市場、2018～2030年
• 皮膚ガン
  • 皮膚がん市場、2018～2030年
• 血液がん
  • 血液がん市場、2018～2030年
• 腎臓がん
  • 腎臓がん市場、2018～2030年
• 肝臓がん
  • 肝がん市場、2018～2030年
• 膵臓がん
  • 膵臓がん市場、2018～2030年
• 卵巣がん
  • 卵巣がん市場、2018～2030年
• その他
  • その他の市場、2018～2030年

第7章 最終用途ビジネス分析

• がん診断薬市場：最終用途変動分析
• 病院
  • 病院市場、2018～2030年
• 研究室
  • 研究室市場、2018～2030年
• その他
  • その他のがん診断薬市場、2018～2030年

第8章 検査型ビジネス分析

• がん診断薬市場：検査タイプ変動分析
• 生検
  • 生検市場、2018～2030年
  • 細針吸引
  • コア生検
  • 外科的生検
  • 皮膚生検/パンチ生検
  • その他
• その他
  • その他のがん診断薬市場、2018～2030年

第9章 製品ビジネス分析

• がん診断薬市場：製品変動分析
• 機器
  • 機器市場、2018～2030年
• 消耗品キット・試薬
  • 消耗品キット・試薬市場、2018～2030年
• ソフトウェア・サービス
  • ソフトウェア・サービス市場、2018～2030年

第10章 地域ビジネス分析

• がん診断薬市場シェア：地域別、2023年・2030年
• 北米
  • 北米がん診断薬市場、2018～2030年
  • 米国
  • カナダ
• 欧州
  • 欧州がん診断薬市場、2018～2030年
  • ドイツ
  • 英国
  • フランス
  • イタリア
  • スペイン
  • デンマーク
  • スウェーデン
  • ノルウェー
• アジア太平洋
  • アジア太平洋がん診断薬市場、2018～2030年
  • 日本
  • 中国
  • インド
  • 韓国
  • オーストラリア
  • タイ
• ラテンアメリカ
  • ラテンアメリカがん診断薬市場、2018～2030年
  • ブラジル
  • メキシコ
  • アルゼンチン
• 中東・アフリカ
  • 中東・アフリカがん診断薬市場、2018～2030年
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • クウェート

第11章 競合情勢

• 参入企業の概要
• 財務実績
• 参入企業
  • 市場リーダー
  • がん診断薬市場シェア分析、2023年
  • 企業プロファイル
  • 戦略マッピング

List of Tables

• Table 1 List of abbreviations
• Table 2 Global cancer diagnostics market, by region, 2018 - 2030 (USD Billion)
• Table 3 Global cancer diagnostics market, by product, 2018 - 2030 (USD Billion)
• Table 4 Global cancer diagnostics market, by type, 2018 - 2030 (USD Billion)
• Table 5 Global cancer diagnostics market, by application, 2018 - 2030 (USD Billion)
• Table 6 Global cancer diagnostics market, by end-use, 2018 - 2030 (USD Billion)
• Table 7 Global cancer diagnostics market, by test type, 2018 - 2030 (USD Billion)
• Table 8 North America cancer diagnostics market, by country, 2018 - 2030 (USD Billion)
• Table 9 North America cancer diagnostics market, by product, 2018 - 2030 (USD Billion)
• Table 10 North America cancer diagnostics market, by type, 2018 - 2030 (USD Billion)
• Table 11 North America cancer diagnostics market, by application, 2018 - 2030 (USD Billion)
• Table 12 North America cancer diagnostics market, by end-use, 2018 - 2030 (USD Billion)
• Table 13 North America cancer diagnostics market, by test type, 2018 - 2030 (USD Billion)
• Table 14 U.S. cancer diagnostics market, by product, 2018 - 2030 (USD Billion)
• Table 15 U.S. cancer diagnostics market, by type, 2018 - 2030 (USD Billion)
• Table 16 U.S. cancer diagnostics market, by application, 2018 - 2030 (USD Billion)
• Table 17 U.S. cancer diagnostics market, by end-use, 2018 - 2030 (USD Billion)
• Table 18 U.S. cancer diagnostics market, by test type, 2018 - 2030 (USD Billion)
• Table 19 Canada cancer diagnostics market, by product, 2018 - 2030 (USD Billion)
• Table 20 Canada cancer diagnostics market, by type, 2018 - 2030 (USD Billion)
• Table 21 Canada cancer diagnostics market, by application, 2018 - 2030 (USD Billion)
• Table 22 Canada cancer diagnostics market, by end-use, 2018 - 2030 (USD Billion)
• Table 23 Canada cancer diagnostics market, by test type, 2018 - 2030 (USD Billion)
• Table 24 Europe cancer diagnostics market, by country, 2018 - 2030 (USD Billion)
• Table 25 Europe cancer diagnostics market, by product, 2018 - 2030 (USD Billion)
• Table 26 Europe cancer diagnostics market, by type, 2018 - 2030 (USD Billion)
• Table 27 Europe cancer diagnostics market, by application, 2018 - 2030 (USD Billion)
• Table 28 Europe cancer diagnostics market, by end-use, 2018 - 2030 (USD Billion)
• Table 29 Europe cancer diagnostics market, by test type, 2018 - 2030 (USD Billion)
• Table 30 UK cancer diagnostics market, by product, 2018 - 2030 (USD Billion)
• Table 31 UK cancer diagnostics market, by type, 2018 - 2030 (USD Billion)
• Table 32 UK cancer diagnostics market, by application, 2018 - 2030 (USD Billion)
• Table 33 UK cancer diagnostics market, by end-use, 2018 - 2030 (USD Billion)
• Table 34 UK cancer diagnostics market, by test type, 2018 - 2030 (USD Billion)
• Table 35 Germany cancer diagnostics market, by product, 2018 - 2030 (USD Billion)
• Table 36 Germany cancer diagnostics market, by type, 2018 - 2030 (USD Billion)
• Table 37 Germany cancer diagnostics market, by application, 2018 - 2030 (USD Billion)
• Table 38 Germany cancer diagnostics market, by end-use, 2018 - 2030 (USD Billion)
• Table 39 Germany cancer diagnostics market, by test type, 2018 - 2030 (USD Billion)
• Table 40 France cancer diagnostics market, by product, 2018 - 2030 (USD Billion)
• Table 41 France cancer diagnostics market, by type, 2018 - 2030 (USD Billion)
• Table 42 France cancer diagnostics market, by application, 2018 - 2030 (USD Billion)
• Table 43 France cancer diagnostics market, by end-use, 2018 - 2030 (USD Billion)
• Table 44 France cancer diagnostics market, by test type, 2018 - 2030 (USD Billion)
• Table 45 Italy cancer diagnostics market, by product, 2018 - 2030 (USD Billion)
• Table 46 Italy cancer diagnostics market, by type, 2018 - 2030 (USD Billion)
• Table 47 Italy cancer diagnostics market, by application, 2018 - 2030 (USD Billion)
• Table 48 Italy cancer diagnostics market, by end-use, 2018 - 2030 (USD Billion)
• Table 49 Italy cancer diagnostics market, by test type, 2018 - 2030 (USD Billion)
• Table 50 Spain cancer diagnostics market, by product, 2018 - 2030 (USD Billion)
• Table 51 Spain cancer diagnostics market, by type, 2018 - 2030 (USD Billion)
• Table 52 Spain cancer diagnostics market, by application, 2018 - 2030 (USD Billion)
• Table 53 Spain cancer diagnostics market, by end-use, 2018 - 2030 (USD Billion)
• Table 54 Spain cancer diagnostics market, by test type, 2018 - 2030 (USD Billion)
• Table 55 Denmark cancer diagnostics market, by product, 2018 - 2030 (USD Billion)
• Table 56 Denmark cancer diagnostics market, by type, 2018 - 2030 (USD Billion)
• Table 57 Denmark cancer diagnostics market, by application, 2018 - 2030 (USD Billion)
• Table 58 Denmark cancer diagnostics market, by end-use, 2018 - 2030 (USD Billion)
• Table 59 Denmark cancer diagnostics market, by test type, 2018 - 2030 (USD Billion)
• Table 60 Sweden cancer diagnostics market, by product, 2018 - 2030 (USD Billion)
• Table 61 Sweden cancer diagnostics market, by type, 2018 - 2030 (USD Billion)
• Table 62 Sweden cancer diagnostics market, by application, 2018 - 2030 (USD Billion)
• Table 63 Sweden cancer diagnostics market, by end-use, 2018 - 2030 (USD Billion)
• Table 64 Sweden cancer diagnostics market, by test type, 2018 - 2030 (USD Billion)
• Table 65 Norway cancer diagnostics market, by product, 2018 - 2030 (USD Billion)
• Table 66 Norway cancer diagnostics market, by type, 2018 - 2030 (USD Billion)
• Table 67 Norway cancer diagnostics market, by application, 2018 - 2030 (USD Billion)
• Table 68 Norway cancer diagnostics market, by end-use, 2018 - 2030 (USD Billion)
• Table 69 Norway cancer diagnostics market, by test type, 2018 - 2030 (USD Billion)
• Table 70 Asia Pacific cancer diagnostics market, by country, 2018 - 2030 (USD Billion)
• Table 71 Asia Pacific cancer diagnostics market, by product, 2018 - 2030 (USD Billion)
• Table 72 Asia Pacific cancer diagnostics market, by type, 2018 - 2030 (USD Billion)
• Table 73 Asia Pacific cancer diagnostics market, by application, 2018 - 2030 (USD Billion)
• Table 74 Asia Pacific cancer diagnostics market, by end-use, 2018 - 2030 (USD Billion)
• Table 75 Asia Pacific cancer diagnostics market, by test type, 2018 - 2030 (USD Billion)
• Table 76 Japan cancer diagnostics market, by product, 2018 - 2030 (USD Billion)
• Table 77 Japan cancer diagnostics market, by type, 2018 - 2030 (USD Billion)
• Table 78 Japan cancer diagnostics market, by application, 2018 - 2030 (USD Billion)
• Table 79 Japan cancer diagnostics market, by end-use, 2018 - 2030 (USD Billion)
• Table 80 Japan cancer diagnostics market, by test type, 2018 - 2030 (USD Billion)
• Table 81 China cancer diagnostics market, by product, 2018 - 2030 (USD Billion)
• Table 82 China cancer diagnostics market, by type, 2018 - 2030 (USD Billion)
• Table 83 China cancer diagnostics market, by application, 2018 - 2030 (USD Billion)
• Table 84 China cancer diagnostics market, by end-use, 2018 - 2030 (USD Billion)
• Table 85 China cancer diagnostics market, by test type, 2018 - 2030 (USD Billion)
• Table 86 India cancer diagnostics market, by product, 2018 - 2030 (USD Billion)
• Table 87 India cancer diagnostics market, by type, 2018 - 2030 (USD Billion)
• Table 88 India cancer diagnostics market, by application, 2018 - 2030 (USD Billion)
• Table 89 India cancer diagnostics market, by end-use, 2018 - 2030 (USD Billion)
• Table 90 India cancer diagnostics market, by test type, 2018 - 2030 (USD Billion)
• Table 91 South Korea cancer diagnostics market, by product, 2018 - 2030 (USD Billion)
• Table 92 South Korea cancer diagnostics market, by type, 2018 - 2030 (USD Billion)
• Table 93 South Korea cancer diagnostics market, by application, 2018 - 2030 (USD Billion)
• Table 94 South Korea cancer diagnostics market, by end-use, 2018 - 2030 (USD Billion)
• Table 95 South Korea cancer diagnostics market, by test type, 2018 - 2030 (USD Billion)
• Table 96 Thailand cancer diagnostics market, by product, 2018 - 2030 (USD Billion)
• Table 97 Thailand cancer diagnostics market, by type, 2018 - 2030 (USD Billion)
• Table 98 Thailand cancer diagnostics market, by application, 2018 - 2030 (USD Billion)
• Table 99 Thailand cancer diagnostics market, by end-use, 2018 - 2030 (USD Billion)
• Table 100 Thailand cancer diagnostics market, by test type, 2018 - 2030 (USD Billion)
• Table 101 Australia cancer diagnostics market, by product, 2018 - 2030 (USD Billion)
• Table 102 Australia cancer diagnostics market, by type, 2018 - 2030 (USD Billion)
• Table 103 Australia cancer diagnostics market, by application, 2018 - 2030 (USD Billion)
• Table 104 Australia cancer diagnostics market, by end-use, 2018 - 2030 (USD Billion)
• Table 105 Australia cancer diagnostics market, by test type, 2018 - 2030 (USD Billion)
• Table 106 Latin America cancer diagnostics market, by country, 2018 - 2030 (USD Billion)
• Table 107 Latin America cancer diagnostics market, by product, 2018 - 2030 (USD Billion)
• Table 108 Latin America cancer diagnostics market, by type, 2018 - 2030 (USD Billion)
• Table 109 Latin America cancer diagnostics market, by application, 2018 - 2030 (USD Billion)
• Table 110 Latin America cancer diagnostics market, by end-use, 2018 - 2030 (USD Billion)
• Table 111 Latin America cancer diagnostics market, by test type, 2018 - 2030 (USD Billion)
• Table 112 Brazil cancer diagnostics market, by product, 2018 - 2030 (USD Billion)
• Table 113 Brazil cancer diagnostics market, by type, 2018 - 2030 (USD Billion)
• Table 114 Brazil cancer diagnostics market, by application, 2018 - 2030 (USD Billion)
• Table 115 Brazil cancer diagnostics market, by end-use, 2018 - 2030 (USD Billion)
• Table 116 Brazil cancer diagnostics market, by test type, 2018 - 2030 (USD Billion)
• Table 117 Mexico cancer diagnostics market, by product, 2018 - 2030 (USD Billion)
• Table 118 Mexico cancer diagnostics market, by type, 2018 - 2030 (USD Billion)
• Table 119 Mexico cancer diagnostics market, by application, 2018 - 2030 (USD Billion)
• Table 120 Mexico cancer diagnostics market, by end-use, 2018 - 2030 (USD Billion)
• Table 121 Mexico cancer diagnostics market, by test type, 2018 - 2030 (USD Billion)
• Table 122 Argentina cancer diagnostics market, by product, 2018 - 2030 (USD Billion)
• Table 123 Argentina cancer diagnostics market, by type, 2018 - 2030 (USD Billion)
• Table 124 Argentina cancer diagnostics market, by application, 2018 - 2030 (USD Billion)
• Table 125 Argentina cancer diagnostics market, by end-use, 2018 - 2030 (USD Billion)
• Table 126 Argentina cancer diagnostics market, by test type, 2018 - 2030 (USD Billion)
• Table 127 Middle East & Africa cancer diagnostics market, by country, 2018 - 2030 (USD Billion)
• Table 128 Middle East & Africa cancer diagnostics market, by product, 2018 - 2030 (USD Billion)
• Table 129 Middle East & Africa cancer diagnostics market, by type, 2018 - 2030 (USD Billion)
• Table 130 Middle East & Africa cancer diagnostics market, by application, 2018 - 2030 (USD Billion)
• Table 131 Middle East & Africa cancer diagnostics market, by end-use, 2018 - 2030 (USD Billion)
• Table 132 Middle East & Africa cancer diagnostics market, by test type, 2018 - 2030 (USD Billion)
• Table 133 South Africa cancer diagnostics market, by product, 2018 - 2030 (USD Billion)
• Table 134 South Africa cancer diagnostics market, by type, 2018 - 2030 (USD Billion)
• Table 135 South Africa cancer diagnostics market, by application, 2018 - 2030 (USD Billion)
• Table 136 South Africa cancer diagnostics market, by end-use, 2018 - 2030 (USD Billion)
• Table 137 South Africa cancer diagnostics market, by test type, 2018 - 2030 (USD Billion)
• Table 138 Saudi Arabia cancer diagnostics market, by product, 2018 - 2030 (USD Billion)
• Table 139 Saudi Arabia cancer diagnostics market, by type, 2018 - 2030 (USD Billion)
• Table 140 Saudi Arabia cancer diagnostics market, by application, 2018 - 2030 (USD Billion)
• Table 141 Saudi Arabia cancer diagnostics market, by end-use, 2018 - 2030 (USD Billion)
• Table 142 Saudi Arabia cancer diagnostics market, by test type, 2018 - 2030 (USD Billion)
• Table 143 UAE cancer diagnostics market, by product, 2018 - 2030 (USD Billion)
• Table 144 UAE cancer diagnostics market, by type, 2018 - 2030 (USD Billion)
• Table 145 UAE cancer diagnostics market, by application, 2018 - 2030 (USD Billion)
• Table 146 UAE cancer diagnostics market, by end-use, 2018 - 2030 (USD Billion)
• Table 147 UAE cancer diagnostics market, by test type, 2018 - 2030 (USD Billion)
• Table 148 Kuwait cancer diagnostics market, by product, 2018 - 2030 (USD Billion)
• Table 149 Kuwait cancer diagnostics market, by type, 2018 - 2030 (USD Billion)
• Table 150 Kuwait cancer diagnostics market, by application, 2018 - 2030 (USD Billion)
• Table 151 Kuwait cancer diagnostics market, by end-use, 2018 - 2030 (USD Billion)
• Table 152 Kuwait cancer diagnostics market, by test type, 2018 - 2030 (USD Billion)

List of Figures

• Fig. 1 Cancer diagnostics market segmentation
• Fig. 2 Market research process
• Fig. 3 Information procurement
• Fig. 4 Primary research pattern
• Fig. 5 Market research approaches
• Fig. 6 Value chain-based sizing & forecasting
• Fig. 7 QFD modeling for market share assessment
• Fig. 8 Market formulation & validation
• Fig. 9 Market snapshot
• Fig. 10 Product and type segment snapshot
• Fig. 11 Application segment snapshot
• Fig. 12 End-use and test type segment snapshot
• Fig. 13 Competitive landscape snapshot
• Fig. 14 Cancer diagnostics market value, 2023 (USD Billion)
• Fig. 15 Market dynamics
• Fig. 16 Incidence of most common cancers globally, 2020
• Fig. 17 Porter's five forces analysis
• Fig. 18 PESTLE analysis
• Fig. 19 Cancer diagnostics market: Product outlook and key takeaways
• Fig. 20 Cancer diagnostics market: Product movement analysis
• Fig. 21 Instruments market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 22 Pathology-based instruments market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 23 Slide staining systems market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 24 Tissue processing systems market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 25 Cell processors market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 26 PCR instruments market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 27 NGS instruments market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 28 Microarrays market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 29 Other pathology-based instruments market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 30 Imaging instruments market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 31 Others market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 32 Consumables market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 33 Antibodies market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 34 Kits & reagents market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 35 Probes market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 36 Others market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 37 Services market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 38 Cancer diagnostics market: Type outlook and key takeaways
• Fig. 39 Cancer diagnostics market: Type movement analysis
• Fig. 40 IVD market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 41 Diagnosis market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 42 Early detection market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 43 Therapy selection market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 44 Monitoring market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 45 Polymerase Chain Reaction (PCR) market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 46 In Situ Hybridization (ISH) market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 47 Immunohistochemistry (IHC) market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 48 Next-generation Sequencing (NGS) market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 49 Microarrays market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 50 Flow cytometry market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 51 Immunoassays market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 52 Other IVD testing technologies market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 53 LDT market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 54 Imaging market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 55 Magnetic Resonance Imaging (MRI) market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 56 Computed Tomography (CT) market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 57 Positron Emission Tomography (PET) market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 58 Mammography market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 59 Ultrasound market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 60 Others market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 61 Cancer diagnostics market: Application outlook and key takeaways
• Fig. 62 Cancer diagnostics market: Application movement analysis
• Fig. 63 Breast cancer market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 64 Colorectal cancer market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 65 Cervical cancer market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 66 Lung cancer market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 67 Prostate cancer market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 68 Skin cancer market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 69 Blood cancer market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 70 Kidney cancer market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 71 Liver cancer market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 72 Pancreatic cancer market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 73 Ovarian cancer market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 74 Others market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 75 Cancer diagnostics market: End-use outlook and key takeaways
• Fig. 76 Cancer diagnostics market: End-use movement analysis
• Fig. 77 Hospitals market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 78 Laboratories market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 79 Others market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 80 Cancer diagnostics market: Test type outlook and key takeaways
• Fig. 81 Cancer diagnostics market: Test type movement analysis
• Fig. 82 Biopsy market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 83 Fine-needle aspiration market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 84 Core biopsy market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 85 Surgical biopsy market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 86 Skin biopsy/punch biopsy market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 87 Others market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 88 Others market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 89 Cancer Diagnostics Market revenue, by region, 2023 & 2030 (USD Billion)
• Fig. 90 Regional marketplace: Key takeaways
• Fig. 91 Regional marketplace: Key takeaways
• Fig. 92 North America cancer diagnostics market estimates and forecasts, 2018 - 2030 (USD Billion)
• Fig. 93 Key country dynamics
• Fig. 94 U.S. cancer diagnostics market estimates and forecasts, 2018 - 2030 (USD Billion)
• Fig. 95 Cancer incidence, 2018-2030
• Fig. 96 Ways to obtain coverage
• Fig. 97 Key country dynamics
• Fig. 98 Canada cancer diagnostics market estimates and forecasts, 2018 - 2030 (USD Billion)
• Fig. 99 Cancer incidence, 2018-2030
• Fig. 100 Europe cancer diagnostics market estimates and forecasts, 2018 - 2030 (USD Billion)
• Fig. 101 Key country dynamics
• Fig. 102 UK cancer diagnostics market estimates and forecasts, 2018 - 2030 (USD Billion)
• Fig. 103 Cancer incidence, 2018-2030
• Fig. 104 Key country dynamics
• Fig. 105 Germany cancer diagnostics market estimates and forecasts, 2018 - 2030 (USD Billion)
• Fig. 106 Cancer incidence, 2018-2030
• Fig. 107 Key country dynamics
• Fig. 108 France cancer diagnostics market estimates and forecasts, 2018 - 2030 (USD Billion)
• Fig. 109 Cancer incidence, 2018-2030
• Fig. 110 Key country dynamics
• Fig. 111 Spain cancer diagnostics market estimates and forecasts, 2018 - 2030 (USD Billion)
• Fig. 112 Cancer incidence, 2018-2030
• Fig. 113 Key country dynamics
• Fig. 114 Italy cancer diagnostics market estimates and forecasts, 2018 - 2030 (USD Billion)
• Fig. 115 Cancer incidence, 2018-2030
• Fig. 116 Key country dynamics
• Fig. 117 Denmark cancer diagnostics market estimates and forecasts, 2018 - 2030 (USD Billion)
• Fig. 118 Target disease prevalence
• Fig. 119 Key country dynamics
• Fig. 120 Sweden cancer diagnostics market estimates and forecasts, 2018 - 2030 (USD Billion)
• Fig. 121 Five most common cancers in Sweden
• Fig. 122 Key country dynamics
• Fig. 123 Norway cancer diagnostics market estimates and forecasts, 2018 - 2030 (USD Billion)
• Fig. 124 Number of new cancer cases in 2020, both sexes, all ages
• Fig. 125 Rest of Europe cancer diagnostics market estimates and forecasts, 2018 - 2030 (USD Billion)
• Fig. 126 Asia Pacific cancer diagnostics market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 127 Key country dynamics
• Fig. 128 Japan cancer diagnostics market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 129 Cancer incidence, 2018 to 2030
• Fig. 130 Key country dynamics
• Fig. 131 China cancer diagnostics market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 132 Cancer incidence, 2018 to 2030
• Fig. 133 China regulatory details
• Fig. 134 Key country dynamics
• Fig. 135 India cancer diagnostics market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 136 Cancer incidence, 2018 to 2030
• Fig. 137 Key country dynamics
• Fig. 138 Australia cancer diagnostics market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 139 Cancer incidence, 2018 to 2030
• Fig. 140 Key country dynamics
• Fig. 141 Thailand cancer diagnostics market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 142 Cancer incidence, 2020 to 2030
• Fig. 143 Key country dynamics
• Fig. 144 South Korea cancer diagnostics market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 145 Cancer incidence 2018 to 2030
• Fig. 146 South Korean regulations in four hierarchical orders
• Fig. 147 South Korea reimbursement scenario
• Fig. 148 Rest of Asia Pacific cancer diagnostics market estimates and forecast, 2018 - 2030 (USD Billion)
• Fig. 149 Latin America cancer diagnostics market estimates and forecasts, 2018 - 2030 (USD Billion)
• Fig. 150 Key country dynamics
• Fig. 151 Brazil cancer diagnostics market estimates and forecasts, 2018 - 2030 (USD Billion)
• Fig. 152 Estimated number of new cancer cases in Brazil
• Fig. 153 Key country dynamics
• Fig. 154 Mexico cancer diagnostics market estimates and forecasts, 2018 - 2030 (USD Billion)
• Fig. 155 Estimated number of new cancer cases in Mexico
• Fig. 156 Key country dynamics
• Fig. 157 Argentina cancer diagnostics market estimates and forecasts, 2018 - 2030 (USD Billion)
• Fig. 158 Estimated number of new cancer cases in Argentina
• Fig. 159 Rest of Latin America cancer diagnostics market estimates and forecasts, 2018 - 2030 (USD Billion)
• Fig. 160 MEA cancer diagnostics market estimates and forecasts, 2018 - 2030 (USD Billion)
• Fig. 161 Key country dynamics
• Fig. 162 South Africa cancer diagnostics market estimates and forecasts, 2018 - 2030 (USD Billion)
• Fig. 163 Cancer prevalence-2018-2030
• Fig. 164 Key country dynamics
• Fig. 165 Saudi Arabia cancer diagnostics market estimates and forecasts, 2018 - 2030 (USD Billion)
• Fig. 166 Cancer prevalence-2018-2030
• Fig. 167 Key country dynamics
• Fig. 168 UAE cancer diagnostics market estimates and forecasts, 2018 - 2030 (USD Billion)
• Fig. 169 Cancer prevalence 2018-2030
• Fig. 170 Key country dynamics
• Fig. 171 Kuwait cancer diagnostics market estimates and forecasts, 2018 - 2030 (USD Billion)
• Fig. 172 Target disease prevalence
• Fig. 173 Key payers in Kuwait
• Fig. 174 Rest of MEA cancer diagnostics market estimates and forecasts, 2018 - 2030 (USD Billion)
• Fig. 175 Key company categorization
• Fig. 176 Company market share analysis, 2023
• Fig. 177 Strategic framework

Cancer Diagnostics Market Growth & Trends:

The global cancer diagnostics market size is expected to reach USD 162.31 billion by 2030, as per the new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 6.16% from 2024 to 2030. Increasing number of programs to raise awareness about cancer by several organizations is a major factor accountable for increased demand for diagnostic products worldwide. Partnerships and collaborations undertaken by the National Cervical Cancer Coalition, WHO, CDC, the U.S. Preventive Services Task Force, & others for increasing cervical cancer screening are among the major factors expected to boost market growth during the forecast period.

Several countries have thus undertaken measures to increase screening for early diagnosis and help existing patients. For instance, Ayushman Bharat and the Prime Minister's National Relief Fund was initiated by the Indian government for patients who require assistance during the treatment. Similarly, the Indian government's Department of Biotechnology signed a contract with Cancer Research UK to conduct research for affordable approaches to diagnosis and treatment.

Liquid biopsy solutions are being increasingly adopted as MCED tests as they are easily accessible for clinical applications. In recent years, they have gained regulatory approval with comprehensive and multi-cancer diagnostic approaches. Breakthrough advancements in the field and ongoing studies for early detection are contributing to market growth. Moreover, technologies such as circulating tumor DNA, extracellular vesicles, and circulating tumor cells are paving the way for better cancer care. Versatile technologies can provide integrated solutions for maximizing the potential of liquid biopsy.

Advantage of using companion diagnostics is the overall reduction in time and costs incurred by pharmaceutical and diagnostic companies. The time required to develop and commercialize a novel molecule generally consists of 10 to 15 years. Co-development of diagnostics and drugs facilitates accelerated regulatory approval processes, which significantly reduces costs. . Since the FDA guidance draft for the development of an IVD companion diagnostic device with a therapeutic product was published in 2016, many manufacturers encourage the development of companion diagnostic assays in the field of oncology. This is anticipated to positively impact market growth during the forecast period.

Cancer Diagnostics Market Report Highlights:

• Based on product, the consumables segment held the largest share of 59.98% in 2023 and is anticipated to grow at the fastest growth rate over the forecast period
• Based on type, in vitro diagnostics (IVD) segment dominated the in 2023 with a share of 52.75% due to the increasing adoption of IVD owing to the rise in testing amid COVID-19 pandemic.
• The breast cancer application segment is expected to grow lucratively over the forecast period due to growth in initiatives to spread awareness across the population and increase in R&D activities.
• Based on end-use, the laboratories segment dominated the market due to efficient outpatient services. The hospitals segment is forecasted grow at a significant rate over the coming years attributed to an increase in the admittance of patients in hospitals
• The biopsy segment is anticipated to grow at a significant growth rate due to various benefits associated with the test, including early detection of the disease
• North America dominated the global cancer diagnostics market in 2023, owing to rise in the number of approvals of new diagnostic tests
• The Asia Pacific is expected to grow considerably in the future owing to due to the rising prevalence and the presence of key players

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation
  • 1.1.1. Market Definitions
• 1.2. Objectives
  • 1.2.1. Objective - 1
  • 1.2.2. Objective - 2
  • 1.2.3. Objective - 3
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased Database
  • 1.4.2. Gvr's Internal Database
  • 1.4.3. Secondary Sources
  • 1.4.4. Primary Research
• 1.5. Information Or Data Analysis
  • 1.5.1. Data Analysis Models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity Flow Analysis
• 1.8. List of Secondary Sources
• 1.9. List of Abbreviations
• 1.10. List of Primary Sources

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Product and Type Snapshot
• 2.3. Application and End-use Snapshot
• 2.4. Test Type Snapshot
• 2.5. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

• 3.1. Market Segmentation and Scope
• 3.2. Market Lineage Outlook
  • 3.2.1. Parent Market Outlook
  • 3.2.2. Related/Ancillary Market Outlook
• 3.3. Market Dynamics
• 3.4. Market Drivers
  • 3.4.1. Rising Prevalence of Cancer
  • 3.4.2. Technological Advancements
  • 3.4.3. Rising Initiatives Undertaken by Public and Private Organizations
  • 3.4.4. Extensive R&D for the Development of Novel Testing Solutions
• 3.5. Market Restraint Analysis
  • 3.5.1. High Cost of Diagnostic Imaging
  • 3.5.2. Radiation Exposure Likely to Limit Usage of CT Scans
  • 3.5.3. Rising Adoption of Refurbished Diagnostic Imaging Systems
• 3.6. Business Environment Analysis
  • 3.6.1. SWOT Analysis; By Factor (Political & Legal, Economic And Technological)
  • 3.6.2. Porter's Five Forces Analysis
  • 3.6.3. COVID-19 Impact Analysis

Chapter 4. Product Business Analysis

• 4.1. Cancer Diagnostics Market: Product Movement Analysis
• 4.2. Instruments
  • 4.2.1. Instruments Market, 2018 - 2030 (USD Billion)
  • 4.2.2. Pathology Based-Instruments
    • 4.2.2.1. Slide Staining Systems
    • 4.2.2.1.1. Slide Staining Systems Market, 2018 - 2030 (USD Billion)
    • 4.2.2.2. Tissue Processing Systems
    • 4.2.2.2.1. Tissue Processing Systems Market, 2018 - 2030 (USD Billion)
    • 4.2.2.3. Cell Processors
    • 4.2.2.3.1. Cell Processors Systems Market, 2018 - 2030 (USD Billion)
    • 4.2.2.4. PCR Instruments
    • 4.2.2.4.1. PCR Instruments Market, 2018 - 2030 (USD Billion)
    • 4.2.2.5. NGS Instruments
    • 4.2.2.5.1. NGS Instruments Market, 2018 - 2030 (USD Billion)
    • 4.2.2.6. Microarrays
    • 4.2.2.6.1. Microarrays Market, 2018 - 2030 (USD Billion)
    • 4.2.2.7. Other Pathology-based Instruments
    • 4.2.2.7.1. Other Pathology-based Instruments Market, 2018 - 2030 (USD Billion)
  • 4.2.3. Imaging Instruments
  • 4.2.4. Others
• 4.3. Consumables
  • 4.3.1. Consumables Market, 2018 - 2030 (USD Billion)
• 4.4. Services
  • 4.4.1. Services Market, 2018 - 2030 (USD Billion)

Chapter 5. Type Business Analysis

• 5.1. Cancer Diagnostics Market: Type Movement Analysis
• 5.2. IVD
  • 5.2.1. IVD Market, 2018 - 2030 (USD Billion)
  • 5.2.2. IVD Market, By Type 2018 - 2030 (USD Billion)
    • 5.2.2.1. Diagnosis
    • 5.2.2.1.1. Diagnosis Market, 2018 - 2030 (USD Billion)
    • 5.2.2.2. Early Detection
    • 5.2.2.2.1. Early Detection Market, 2018 - 2030 (USD Billion)
    • 5.2.2.3. Therapy Selection
    • 5.2.2.3.1. Therapy Selection Market, 2018 - 2030 (USD Billion)
    • 5.2.2.4. Monitoring
    • 5.2.2.4.1. Monitoring Market, 2018 - 2030 (USD Billion)
  • 5.2.3. IVD Market, By Technology 2018 - 2030 (USD Billion)
    • 5.2.3.1. Polymerase Chain Reaction (PCR)
    • 5.2.3.1.1. Polymerase Chain Reaction (PCR) Market, 2018 - 2030 (USD Billion)
    • 5.2.3.2. In Situ Hybridization (ISH)
    • 5.2.3.2.1. In Situ Hybridization (ISH) Market, 2018 - 2030 (USD Billion)
    • 5.2.3.3. Immunohistochemistry (IHC)
    • 5.2.3.3.1. Immunohistochemistry (IHC) Market, 2018 - 2030 (USD Billion)
    • 5.2.3.4. Next-generation Sequencing (NGS)
    • 5.2.3.4.1. Next-generation Sequencing (NGS) Market, 2018 - 2030 (USD Billion)
    • 5.2.3.5. Microarrays
    • 5.2.3.5.1. Microarrays Market, 2018 - 2030 (USD Billion)
    • 5.2.3.6. Flow Cytometry
    • 5.2.3.6.1. Flow Cytometry Market, 2018 - 2030 (USD Billion)
    • 5.2.3.7. Immunoassays
    • 5.2.3.7.1. Immunoassays Market, 2018 - 2030 (USD Billion)
    • 5.2.3.8. Other IVD Testing Technologies
    • 5.2.3.8.1. Other IVD Testing Technologies Market, 2018 - 2030 (USD Billion)
• 5.3. LDT
  • 5.3.1. LDT Market, 2018 - 2030 (USD Billion)
• 5.4. Imaging
  • 5.4.1. Imaging Market, 2018 - 2030 (USD Billion)
  • 5.4.2. Magnetic Resonance Imaging (MRI)
    • 5.4.2.1. Magnetic Resonance Imaging (MRI) Market, 2018 - 2030 (USD Billion)
  • 5.4.3. Computed Tomography (CT)
    • 5.4.3.1. Computed Tomography (CT) Market, 2018 - 2030 (USD Billion)
  • 5.4.4. Positron Emission Tomography (PET)
    • 5.4.4.1. Positron Emission Tomography (PET) Market, 2018 - 2030 (USD Billion)
  • 5.4.5. Mammography
    • 5.4.5.1. Mammography Market, 2018 - 2030 (USD Billion)
  • 5.4.6. Ultrasound
    • 5.4.6.1. Ultrasound Market, 2018 - 2030 (USD Billion)
  • 5.4.7. Others
    • 5.4.7.1. Others Market, 2018 - 2030 (USD Billion)

Chapter 6. Application Business Analysis

• 6.1. Cancer Diagnostics Market: Application Movement Analysis
• 6.2. Breast Cancer
  • 6.2.1. Breast Cancer Market, 2018 - 2030 (USD Billion)
• 6.3. Colorectal Cancer
  • 6.3.1. Colorectal Cancer Market, 2018 - 2030 (USD Billion)
• 6.4. Cervical Cancer
  • 6.4.1. Cervical Cancer Market, 2018 - 2030 (USD Billion)
• 6.5. Lung Cancer
  • 6.5.1. Lung Cancer Market, 2018 - 2030 (USD Billion)
• 6.6. Prostate Cancer
  • 6.6.1. Prostate Cancer Market, 2018 - 2030 (USD Billion)
• 6.7. Skin Cancer
  • 6.7.1. Skin Cancer Market, 2018 - 2030 (USD Billion)
• 6.8. Blood Cancer
  • 6.8.1. Blood Cancer Market, 2018 - 2030 (USD Billion)
• 6.9. Kidney Cancer
  • 6.9.1. Kidney Cancer Market, 2018 - 2030 (USD Billion)
• 6.10. Liver Cancer
  • 6.10.1. Liver Cancer Market, 2018 - 2030 (USD Billion)
• 6.11. Pancreatic Cancer
  • 6.11.1. Pancreatic Cancer Market, 2018 - 2030 (USD Billion)
• 6.12. Ovarian Cancer
  • 6.12.1. Ovarian Cancer Market, 2018 - 2030 (USD Billion)
• 6.13. Others
  • 6.13.1. Others Market, 2018 - 2030 (USD Billion)

Chapter 7. End-Use Business Analysis

• 7.1. Cancer Diagnostics Market: End-Use Movement Analysis
• 7.2. Hospitals
  • 7.2.1. Hospitals Market, 2018 - 2030 (USD Billion)
• 7.3. Laboratories
  • 7.3.1. Laboratories Market, 2018 - 2030 (USD Billion)
• 7.4. Others
  • 7.4.1. Others Cancer Diagnostics Market, 2018 - 2030 (USD Billion)

Chapter 8. Test Type Business Analysis

• 8.1. Cancer Diagnostics Market: Test Type Movement Analysis
• 8.2. Biopsy
  • 8.2.1. Biopsy Market, 2018 - 2030 (USD Billion)
  • 8.2.2. Fine-needle Aspiration
    • 8.2.2.1. Fine-needle Aspiration Market, 2018 - 2030 (USD Billion)
  • 8.2.3. Core Biopsy
    • 8.2.3.1. Core Biopsy Market, 2018 - 2030 (USD Billion)
  • 8.2.4. Surgical Biopsy
    • 8.2.4.1. Surgical Biopsy Market, 2018 - 2030 (USD Billion)
  • 8.2.5. Skin Biopsy /Punch Biopsy
    • 8.2.5.1. Skin Biopsy /Punch Biopsy Market, 2018 - 2030 (USD Billion)
  • 8.2.6. Others
    • 8.2.6.1. Others Market, 2018 - 2030 (USD Billion)
• 8.3. Others
  • 8.3.1. Others Cancer Diagnostics Market, 2018 - 2030 (USD Billion)

Chapter 9. Product Business Analysis

• 9.1. Cancer Diagnostics Market: Product Movement Analysis
• 9.2. Instruments
  • 9.2.1. Instruments Market, 2018 - 2030 (USD Billion)
• 9.3. Consumables Kits and Reagents
  • 9.3.1. Consumables Kits and Reagents Market, 2018 - 2030 (USD Billion)
• 9.4. Software and Services
  • 9.4.1. Software and Services Market, 2018 - 2030 (USD Billion)

Chapter 10. Regional Business Analysis

• 10.1. Cancer Diagnostics Market Share By Region, 2023 & 2030
• 10.2. North America
  • 10.2.1. North America Cancer diagnostics market, 2018 - 2030 (USD Billion)
  • 10.2.2. U.S.
    • 10.2.2.1. Key Country Dynamics
    • 10.2.2.2. Target Disease Prevalence
    • 10.2.2.3. Competitive Scenario
    • 10.2.2.4. Regulatory Framework
    • 10.2.2.5. Reimbursement Scenario
    • 10.2.2.6. U.S. Cancer diagnostics market, 2018 - 2030 (USD BILLION)
  • 10.2.3. Canada
    • 10.2.3.1. Key Country Dynamics
    • 10.2.3.2. Target Disease Prevalence
    • 10.2.3.3. Competitive Scenario
    • 10.2.3.4. Regulatory Framework
    • 10.2.3.5. Reimbursement Scenario
    • 10.2.3.6. Canada Cancer diagnostics market, 2018 - 2030 (USD Billion)
• 10.3. Europe
  • 10.3.1. Europe Cancer diagnostics market, 2018 - 2030 (USD Billion)
  • 10.3.2. Germany
    • 10.3.2.1. Key Country Dynamics
    • 10.3.2.2. Target Disease Prevalence
    • 10.3.2.3. Competitive Scenario
    • 10.3.2.4. Regulatory Framework
    • 10.3.2.5. Reimbursement Scenario
    • 10.3.2.6. Germany Cancer diagnostics market, 2018 - 2030 (USD Billion)
  • 10.3.3. UK
    • 10.3.3.1. Key Country Dynamics
    • 10.3.3.2. Target Disease Prevalence
    • 10.3.3.3. Competitive Scenario
    • 10.3.3.4. Regulatory Framework
    • 10.3.3.5. Reimbursement Scenario
    • 10.3.3.6. UK Cancer diagnostics market, 2018 - 2030 (USD Billion)
  • 10.3.4. France
    • 10.3.4.1. Key Country Dynamics
    • 10.3.4.2. Target Disease Prevalence
    • 10.3.4.3. Competitive Scenario
    • 10.3.4.4. Regulatory Framework
    • 10.3.4.5. Reimbursement Scenario
    • 10.3.4.6. France Cancer diagnostics market, 2018 - 2030 (USD Billion)
  • 10.3.5. Italy
    • 10.3.5.1. Key Country Dynamics
    • 10.3.5.2. Target Disease Prevalence
    • 10.3.5.3. Competitive Scenario
    • 10.3.5.4. Regulatory Framework
    • 10.3.5.5. Reimbursement Scenario
    • 10.3.5.6. Italy Cancer diagnostics market, 2018 - 2030 (USD Billion)
  • 10.3.6. Spain
    • 10.3.6.1. Key Country Dynamics
    • 10.3.6.2. Target Disease Prevalence
    • 10.3.6.3. Competitive Scenario
    • 10.3.6.4. Regulatory Framework
    • 10.3.6.5. Reimbursement Scenario
    • 10.3.6.6. Spain Cancer diagnostics market, 2018 - 2030 (USD Billion)
  • 10.3.7. Denmark
    • 10.3.7.1. Key Country Dynamics
    • 10.3.7.2. Target Disease Prevalence
    • 10.3.7.3. Competitive Scenario
    • 10.3.7.4. Regulatory Framework
    • 10.3.7.5. Reimbursement Scenario
    • 10.3.7.6. Denmark Cancer diagnostics market, 2018 - 2030 (USD Billion)
  • 10.3.8. Sweden
    • 10.3.8.1. Key Country Dynamics
    • 10.3.8.2. Target Disease Prevalence
    • 10.3.8.3. Competitive Scenario
    • 10.3.8.4. Regulatory Framework
    • 10.3.8.5. Reimbursement Scenario
    • 10.3.8.6. Sweden Cancer diagnostics market, 2018 - 2030 (USD Billion)
  • 10.3.9. Norway
    • 10.3.9.1. Key Country Dynamics
    • 10.3.9.2. Target Disease Prevalence
    • 10.3.9.3. Competitive Scenario
    • 10.3.9.4. Regulatory Framework
    • 10.3.9.5. Reimbursement Scenario
    • 10.3.9.6. Norway Cancer diagnostics market, 2018 - 2030 (USD Billion)
• 10.4. Asia Pacific
  • 10.4.1. Asia Pacific Cancer diagnostics market, 2018 - 2030 (USD Billion)
  • 10.4.2. Japan
    • 10.4.2.1. Key Country Dynamics
    • 10.4.2.2. Target Disease Prevalence
    • 10.4.2.3. Competitive Scenario
    • 10.4.2.4. Regulatory Framework
    • 10.4.2.5. Reimbursement Scenario
    • 10.4.2.6. Japan Cancer diagnostics market, 2018 - 2030 (USD Billion)
  • 10.4.3. China
    • 10.4.3.1. Key Country Dynamics
    • 10.4.3.2. Target Disease Prevalence
    • 10.4.3.3. Competitive Scenario
    • 10.4.3.4. Regulatory Framework
    • 10.4.3.5. Reimbursement Scenario
    • 10.4.3.6. China Cancer diagnostics market, 2018 - 2030 (USD Billion)
  • 10.4.4. India
    • 10.4.4.1. Key Country Dynamics
    • 10.4.4.2. Target Disease Prevalence
    • 10.4.4.3. Competitive Scenario
    • 10.4.4.4. Regulatory Framework
    • 10.4.4.5. Reimbursement Scenario
    • 10.4.4.6. India Cancer diagnostics market, 2018 - 2030 (USD Billion)
  • 10.4.5. South Korea
    • 10.4.5.1. Key Country Dynamics
    • 10.4.5.2. Target Disease Prevalence
    • 10.4.5.3. Competitive Scenario
    • 10.4.5.4. Regulatory Framework
    • 10.4.5.5. Reimbursement Scenario
    • 10.4.5.6. South Korea Cancer diagnostics market, 2018 - 2030 (USD Billion)
  • 10.4.6. Australia
    • 10.4.6.1. Key Country Dynamics
    • 10.4.6.2. Target Disease Prevalence
    • 10.4.6.3. Competitive Scenario
    • 10.4.6.4. Regulatory Framework
    • 10.4.6.5. Reimbursement Scenario
    • 10.4.6.6. Australia Cancer diagnostics market, 2018 - 2030 (USD Billion)
  • 10.4.7. Thailand
    • 10.4.7.1. Key Country Dynamics
    • 10.4.7.2. Target Disease Prevalence
    • 10.4.7.3. Competitive Scenario
    • 10.4.7.4. Regulatory Framework
    • 10.4.7.5. Reimbursement Scenario
    • 10.4.7.6. Thailand Cancer diagnostics market, 2018 - 2030 (USD Billion)
• 10.5. Latin America
  • 10.5.1. Latin America Cancer diagnostics market, 2018 - 2030 (USD Billion)
  • 10.5.2. Brazil
    • 10.5.2.1. Key Country Dynamics
    • 10.5.2.2. Target Disease Prevalence
    • 10.5.2.3. Competitive Scenario
    • 10.5.2.4. Regulatory Framework
    • 10.5.2.5. Reimbursement Scenario
    • 10.5.2.6. Brazil Cancer diagnostics market, 2018 - 2030 (USD Billion)
  • 10.5.3. Mexico
    • 10.5.3.1. Key Country Dynamics
    • 10.5.3.2. Target Disease Prevalence
    • 10.5.3.3. Competitive Scenario
    • 10.5.3.4. Regulatory Framework
    • 10.5.3.5. Reimbursement Scenario
    • 10.5.3.6. Mexico Cancer diagnostics market, 2018 - 2030 (USD Billion)
  • 10.5.4. Argentina
    • 10.5.4.1. Key Country Dynamics
    • 10.5.4.2. Target Disease Prevalence
    • 10.5.4.3. Competitive Scenario
    • 10.5.4.4. Regulatory Framework
    • 10.5.4.5. Reimbursement Scenario
    • 10.5.4.6. Argentina Cancer diagnostics market, 2018 - 2030 (USD Billion)
• 10.6. MEA
  • 10.6.1. MEA Cancer diagnostics market, 2018 - 2030 (USD Billion)
  • 10.6.2. South Africa
    • 10.6.2.1. Key Country Dynamics
    • 10.6.2.2. Target Disease Prevalence
    • 10.6.2.3. Competitive Scenario
    • 10.6.2.4. Regulatory Framework
    • 10.6.2.5. Reimbursement Scenario
    • 10.6.2.6. South Africa Cancer diagnostics market, 2018 - 2030 (USD Billion)
  • 10.6.3. Saudi Arabia
    • 10.6.3.1. Key Country Dynamics
    • 10.6.3.2. Target Disease Prevalence
    • 10.6.3.3. Competitive Scenario
    • 10.6.3.4. Regulatory Framework
    • 10.6.3.5. Reimbursement Scenario
    • 10.6.3.6. Saudi Arabia Cancer diagnostics market, 2018 - 2030 (USD Billion)
  • 10.6.4. UAE
    • 10.6.4.1. Key Country Dynamics
    • 10.6.4.2. Target Disease Prevalence
    • 10.6.4.3. Competitive Scenario
    • 10.6.4.4. Regulatory Framework
    • 10.6.4.5. Reimbursement Scenario
    • 10.6.4.6. UAE Cancer diagnostics market, 2018 - 2030 (USD Billion)
  • 10.6.5. Kuwait
    • 10.6.5.1. Key Country Dynamics
    • 10.6.5.2. Target Disease Prevalence
    • 10.6.5.3. Competitive Scenario
    • 10.6.5.4. Regulatory Framework
    • 10.6.5.5. Reimbursement Scenario
    • 10.6.5.6. Kuwait Cancer diagnostics market, 2018 - 2030 (USD Billion)

Chapter 11. Competitive Landscape

• 11.1. Participant's overview
• 11.2. Financial performance
• 11.3. Participant categorization
  • 11.3.1. Market Leaders
  • 11.3.2. Cancer Diagnostics Market Share Analysis, 2023
  • 11.3.3. Company Profiles
    • 11.3.3.1. ABBOTT
    • 11.3.3.1.1. Company Overview
    • 11.3.3.1.2. Financial Performance
    • 11.3.3.1.3. Product Benchmarking
    • 11.3.3.1.4. Strategic Initiatives
    • 11.3.3.2. GE HEALTHCARE
    • 11.3.3.2.1. Company Overview
    • 11.3.3.2.2. Financial Performance
    • 11.3.3.2.3. Product Benchmarking
    • 11.3.3.2.4. Strategic Initiatives
    • 11.3.3.3. F. HOFFMANN-LA ROCHE LTD.
    • 11.3.3.3.1. Company Overview
    • 11.3.3.3.2. Financial Performance
    • 11.3.3.3.3. Product Benchmarking
    • 11.3.3.3.4. Strategic Initiatives
    • 11.3.3.4. QIAGEN
    • 11.3.3.4.1. Company Overview
    • 11.3.3.4.2. Financial Performance
    • 11.3.3.4.3. Product Benchmarking
    • 11.3.3.4.4. Strategic Initiatives
    • 11.3.3.5. BD
    • 11.3.3.5.1. Company Overview
    • 11.3.3.5.2. Financial Performance
    • 11.3.3.5.3. Product Benchmarking
    • 11.3.3.5.4. Strategic Initiatives
    • 11.3.3.6. SIEMENS HEALTHCARE GMBH
    • 11.3.3.6.1. Company Overview
    • 11.3.3.6.2. Financial Performance
    • 11.3.3.6.3. Product Benchmarking
    • 11.3.3.6.4. Strategic Initiatives
    • 11.3.3.7. THERMO FISHER SCIENTIFIC, INC.
    • 11.3.3.7.1. Company Overview
    • 11.3.3.7.2. Financial Performance
    • 11.3.3.7.3. Product Benchmarking
    • 11.3.3.7.4. Strategic Initiatives
    • 11.3.3.8. HOLOGIC, INC.
    • 11.3.3.8.1. Company Overview
    • 11.3.3.8.2. Financial Performance
    • 11.3.3.8.3. Product Benchmarking
    • 11.3.3.8.4. Strategic Initiatives
    • 11.3.3.9. KONINKLIJKE PHILIPS N.V. (PHILIPS)
    • 11.3.3.9.1. Company Overview
    • 11.3.3.9.2. Financial Performance
    • 11.3.3.9.3. Product Benchmarking
    • 11.3.3.9.4. Strategic Initiatives
    • 11.3.3.10. ILLUMINA, INC.
    • 11.3.3.10.1. Company Overview
    • 11.3.3.10.2. Financial Performance
    • 11.3.3.10.3. Product Benchmarking
    • 11.3.3.10.4. Strategic Initiatives
  • 11.3.4. Strategy Mapping
    • 11.3.4.1. Expansion
    • 11.3.4.2. Acquisition
    • 11.3.4.3. Collaborations
    • 11.3.4.4. Disease Type/Drug Class Launch
    • 11.3.4.5. Partnerships
    • 11.3.4.6. Others